MH002

Ulcerative Colitis (mild-to-moderate)

Phase 2aActive

Key Facts

Indication
Ulcerative Colitis (mild-to-moderate)
Phase
Phase 2a
Status
Active
Company

About MRM Health

MRM Health is a Belgian clinical-stage biotech pioneering a novel approach to live biotherapeutic products (LBPs) through its disruptive CORAL® platform. This technology enables the rational design and scalable manufacturing of optimized, disease-focused microbial consortia, aiming for superior efficacy and safety. The company has demonstrated clinical proof-of-concept in IBD, is advancing a pipeline in other inflammatory and immuno-oncology indications, and is backed by a strong syndicate of strategic and financial investors. Its end-to-end capabilities and academic partnerships position it as a key player in the evolving microbiome therapeutics field.

View full company profile

About MRM Health

MRM Health is a Belgian clinical-stage biotech pioneering a novel approach to live biotherapeutic products (LBPs) through its disruptive CORAL® platform. This technology enables the rational design and scalable manufacturing of optimized, disease-focused microbial consortia, aiming for superior efficacy and safety. The company has demonstrated clinical proof-of-concept in IBD, is advancing a pipeline in other inflammatory and immuno-oncology indications, and is backed by a strong syndicate of strategic and financial investors. Its end-to-end capabilities and academic partnerships position it as a key player in the evolving microbiome therapeutics field.

View full company profile